Arcadia Investment Management Corp MI boosted its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 1.5% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 46,655 shares of the medical research company’s stock after buying an additional 695 shares during the quarter. Thermo Fisher Scientific makes up about 2.5% of Arcadia Investment Management Corp MI’s investment portfolio, making the stock its 7th largest position. Arcadia Investment Management Corp MI’s holdings in Thermo Fisher Scientific were worth $8,859,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other hedge funds also recently made changes to their positions in TMO. Bank of Nova Scotia Trust Co. bought a new stake in shares of Thermo Fisher Scientific during the third quarter worth $106,000. Ropes Wealth Advisors LLC raised its position in shares of Thermo Fisher Scientific by 15.8% during the second quarter. Ropes Wealth Advisors LLC now owns 710 shares of the medical research company’s stock worth $124,000 after acquiring an additional 97 shares during the last quarter. Atlantic Trust LLC bought a new stake in shares of Thermo Fisher Scientific during the second quarter worth $138,000. Acrospire Investment Management LLC raised its position in shares of Thermo Fisher Scientific by 66.7% during the second quarter. Acrospire Investment Management LLC now owns 1,000 shares of the medical research company’s stock worth $174,000 after acquiring an additional 400 shares during the last quarter. Finally, Glassman Wealth Services raised its position in shares of Thermo Fisher Scientific by 23.1% during the second quarter. Glassman Wealth Services now owns 1,039 shares of the medical research company’s stock worth $181,000 after acquiring an additional 195 shares during the last quarter. 86.11% of the stock is currently owned by institutional investors and hedge funds.
TMO has been the subject of a number of recent analyst reports. Zacks Investment Research upgraded Thermo Fisher Scientific from a “hold” rating to a “buy” rating and set a $215.00 price objective for the company in a report on Tuesday, October 31st. Leerink Swann reiterated an “outperform” rating and issued a $200.00 price objective (down previously from $216.00) on shares of Thermo Fisher Scientific in a report on Monday, December 4th. Evercore ISI assumed coverage on Thermo Fisher Scientific in a research note on Wednesday, January 3rd. They issued an “outperform” rating and a $220.00 target price for the company. Deutsche Bank set a $226.00 target price on Thermo Fisher Scientific and gave the company a “buy” rating in a research note on Thursday, October 26th. Finally, BTIG Research started coverage on Thermo Fisher Scientific in a research note on Friday, January 5th. They issued a “buy” rating and a $230.00 target price for the company. Two research analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $220.50.
In related news, SVP Gregory J. Herrema sold 33,327 shares of the stock in a transaction that occurred on Friday, February 2nd. The stock was sold at an average price of $219.70, for a total transaction of $7,321,941.90. Following the sale, the senior vice president now owns 60,471 shares of the company’s stock, valued at $13,285,478.70. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Marc N. Casper sold 50,000 shares of the stock in a transaction that occurred on Friday, December 15th. The stock was sold at an average price of $191.74, for a total value of $9,587,000.00. Following the sale, the chief executive officer now directly owns 302,577 shares in the company, valued at approximately $58,016,113.98. The disclosure for this sale can be found here. In the last quarter, insiders have sold 94,327 shares of company stock worth $19,260,542. 0.49% of the stock is owned by corporate insiders.
Thermo Fisher Scientific Inc. (NYSE TMO) traded down $1.26 on Wednesday, reaching $202.24. The company had a trading volume of 169,856 shares, compared to its average volume of 1,640,158. The company has a quick ratio of 0.92, a current ratio of 1.35 and a debt-to-equity ratio of 0.74. The company has a market capitalization of $81,110.00, a price-to-earnings ratio of 36.10, a PEG ratio of 1.50 and a beta of 1.11. Thermo Fisher Scientific Inc. has a fifty-two week low of $151.74 and a fifty-two week high of $226.44.
Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings data on Wednesday, January 31st. The medical research company reported $2.79 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.66 by $0.13. The firm had revenue of $6.05 billion for the quarter, compared to analyst estimates of $5.72 billion. Thermo Fisher Scientific had a return on equity of 8.49% and a net margin of 8.77%. The business’s revenue for the quarter was up 22.1% compared to the same quarter last year. During the same quarter in the prior year, the company earned $2.41 earnings per share. equities research analysts anticipate that Thermo Fisher Scientific Inc. will post 10.81 earnings per share for the current year.
The company also recently announced a quarterly dividend, which will be paid on Monday, April 16th. Stockholders of record on Thursday, March 15th will be paid a dividend of $0.17 per share. The ex-dividend date of this dividend is Wednesday, March 14th. This represents a $0.68 dividend on an annualized basis and a dividend yield of 0.34%. This is a positive change from Thermo Fisher Scientific’s previous quarterly dividend of $0.15. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 10.71%.
TRADEMARK VIOLATION WARNING: “Thermo Fisher Scientific Inc. (TMO) is Arcadia Investment Management Corp MI’s 7th Largest Position” was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece of content on another publication, it was stolen and reposted in violation of U.S. & international copyright law. The original version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/02/14/thermo-fisher-scientific-inc-tmo-position-increased-by-arcadia-investment-management-corp-mi.html.
Thermo Fisher Scientific Profile
Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.
Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.